Dexmedetomidine for reducing succinylcholine indused myalgia in patients undergoing Electroconvulsive therapy.

To Evaluate Efficacy of Dexmedetomidine for Reducing Sucicnylcholine Induced Myalgia in Patients undergoing Electro convulsive Therapy. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097565

Enrollment

100

Registered

2025-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group D: Interventional group will recieve low dose dexmeditomidine (0.25 mcg per kg) diluted in 100 ml Normal Saline given intravenously over 10 minutes before electrocounvulsive thera

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to sign informed consent. Patient belonging to ASA physical status 1 and 2. Patients undergoing Electroconvulsive therapy.

Exclusion criteria

Exclusion criteria: Patients unwilling to participate in study. Patient with BMI more than 30 kg/m2. Patient who are deaf or incapable of understanding the language. Patient belonging to ASA physical status 3. Patients with history of allergy to an adrenergic agonist. Pregnancy and lactating women.

Design outcomes

Primary

Measure	Time frame
This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations and myalgia due to sucicnylcholine during electro convulsive therapy.Timepoint: This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations immediately after giving Sccinylcholine and myalgia due to sucicnylcholine after 60 minutes of electro convulsive therapy.	—

Measure

Time frame

This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations and myalgia due to sucicnylcholine during electro convulsive therapy.Timepoint: This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations immediately after giving Sccinylcholine and myalgia due to sucicnylcholine after 60 minutes of electro convulsive therapy.

—

Secondary

Measure	Time frame
Effect of Dexmedetomidine in attenuating blood pressure & heart rate during electro convulsive therapy.Timepoint: At Base line, 5 min after drug intervention, During ECT, 3 min, 5 min, 10 min, 20 min, 30 min after ECT	—

Countries

India

Contacts

Public ContactDr SARA MARRY THOMAS

Smt Bhailal Kothari Shah Medical Institute and Research Centre Vadodara, Gujarat.

sara.cinosh@gmail.com9646500158

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026